Silica-Based Nanovectors: From Mother Nature to Biomedical Applications by Terracciano, Monica et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Silica-Based Nanovectors: From Mother Nature to
Biomedical Applications
Monica Terracciano, Luca De Stefano,
Hélder A. Santos, Nicola M. Martucci, Angela Tino,
Immacolata Ruggiero, Ivo Rendina,
Nunzia Migliaccio, Claudia Tortiglione,
Annalisa Lamberti and Ilaria Rea
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63191
Abstract
Diatomite is a natural porous silica material of sedimentary origin, formed by remains
of diatom skeletons called “frustules.” The abundance in many areas of the world and
the peculiar physico-chemical properties made diatomite an intriguing material for
several  applications  ranging  from  food  production  to  pharmaceutics.  However,
diatomite is a material still rarely used in biomedical applications. In this chapter, the
properties of diatom frustules reduced to nanoparticles, with an average diameter less
than 350 nm, as potential drug vectors are described. Their biocompatibility, cellular
uptake,  and  capability  to  transport  molecules  inside  cancer  cells  are  discussed.
Preliminary studies of in vivo toxicity are also presented.
Keywords: diatomite, porous material, nanovector, bioconjugation, drug delivery
1. Introduction
Nanomedicine  is  an  innovative  research  field  combining  nanotechnology and medicine,
radically changing the healthcare drug delivery scenario, in particular in the cancer treat‐
ment [1]. The application of nanotechnology in the cancer therapy is expected to solve a
number of issues associated with conventional therapeutic agents, including lack of target‐
ing capability, nonspecific distribution, systemic toxicity, and low therapeutic index [2, 3].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Nanotechnology has provided the opportunity to get direct access to the cancerous cells
selectively with increased drug localization and cellular uptake, making the therapy more
patients’ compliant, efficient, and painless. Moreover, nano-based systems allow delivery of
poor water-soluble molecules (e.g., most of the anticancer drugs) difficult to administer and
can also protect the new therapeutics molecules, such as oligonucleotide analogs (e.g., siRNA)
from degradation, preserving their therapeutic efficacy while in the blood circulation [3, 4].
Thus, the aim of nanomedicine in cancer therapy is the production of nanoparticles (NPs) able
to deliver a drug to a specific site enhancing local drug molecules accumulation and reduc‐
ing systemic toxicity [5–7].  Different types of  organic and inorganic NPs including lipo‐
somes,  micelles,  nanotubes,  and  porous  silicon  (PSi)  nanostructures  have  already  been
investigated for drug delivery purposes [8–13]. In particular, PSi is one of the most inorgan‐
ic material used in biomedicine due to its unique properties such as high-specific surface area,
tunable  pores  size,  biocompatibility,  non-toxicity,  high  loading  capability,  controllable
dissolution kinetic  [1,  14,  15].  Moreover,  PSi  surface  can be  easily  modified using well-
known silane and silanol chemistries in order to incorporate gold and magnetic NPs giving
to the hybrid complex (i.e., PSi nanocarrier + metallic or magnetic NP) additional diagnostic
and therapeutic functions [16].
In recent years, diatomite, a natural porous silica-based material with similar physico-chemical
properties to man-made fabricated PSi, has been suggested as feasible alternative to synthetic
porous media for biomedical applications [17–20]. Diatomite is a compound of sedimentary
origin formed by remains of diatoms deposited on the bottom of seas or lakes [21, 22]. Due to
its peculiar properties including highly ordered pore structure, high-specific surface area,
modifiable surface chemistry, biocompatibility, non-toxicity, low cost, optical, and photonic
properties, diatomite has been used in different applications ranging from optics and photonics
to biosensing [23–27]. Despite these properties and the recognition by the Food and Drug
Administration (FDA) as Generally Recognized as Safe (GRAS) for foods and pharmaceuticals
production, its use in nanomedicine is still surprisingly undervalued [28]. Recently, diatomite
has been explored as microcapsules for oral drug delivery resulting in a non-cytotoxic
biomaterial with high potential to improve the bioavailability of loaded oral drugs [20]. To
date, there is only one manuscript on the intravenous injection of diatomite microparticles into
mice, which investigates the biodistribution and tissue damage of this material. This study
demonstrated that none of the animals exhibited any observable abnormalities in the major
organs after diatomite injections [29]. Over the last few years, diatomite frustules reduced to
nanoparticles have been explored as potential nanocarriers for biomedical applications [30, 31].
In this chapter, the properties of diatomite nanoparticles as non-toxic nanocarriers are
described. Different surface functionalization strategies performed in order to transport
molecules inside cancer cells and to improve diatomite NPs biocompatibility and cellular
internalization are summarized. Preliminary studies of in vivo toxicity are also reported.
2. Diatomite nanoparticles (DNPs)
Diatomite is a material of sedimentary origin, formed by siliceous skeleton (called “frustule”)
of diatoms, unicellular microalgae, deposited on the bottom of seas, or lakes over centuries.
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Due to the presence of diatom frustules with different size (ranging from 2 μm to 2 mm) and
shape, diatomite morphology can be very complicated (Figure 1) [32, 33].
Figure 1. Diatoms by Ernst Haeckel in ‘Kunstformen der Natur’ 1904 (Reproduced from Ref. [32]).
Diatomite is characterized by highly porous structure with a large specific surface area up to
200 m2/g [34]. Its fundamental constituent is amorphous silicon dioxide, even if it can contain
organic and metallic impurities (e.g., MgO, Al2O3, Fe2O3) coming from environment [35, 36].
Several processes, including calcination and hot acid treatments, have been developed in order
to remove these contaminations from frustules [37, 38].
The abundance in many areas of the world and the peculiar physico-chemical properties (e.g.,
chemical stability, non-toxicity) made diatomite an intriguing material for several applications
ranging from food production to pharmaceutics [39–41].
In recent years, diatom frustules have been investigated as porous platform in several
innovative biotechnological applications [42, 43]; the silica surface of diatoms can be easily
modified with different functional groups (–SH, –NH2, –COOH,) for the immobilization of
biomolecular probes (DNA, proteins, antibodies) using the reactive silanol (Si–OH) groups
present on it [44]. Recent works reported the surface chemical modification of a marine diatom
with an antibody used as bioprobe; photoluminescence and fluorescence microscopy were
used in order to investigate the antibody-antigen molecular recognition [45, 46]. Figure 2
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shows an image of marine diatom Coscinodiscus wailesii functionalized with an antibody after
the interaction with the corresponding rhodamine labeled antigen; the dose-response curve of
biosensor (i.e., diatom platform + antibody) is also reported [45].
Figure 2. (A) Image of diatom frustules after the interaction between an antibody, covalently linked on them, and the
corresponding rhodamine labeled antigen. (B) Fluorescence intensity versus antigen concentration (Reproduced from
Ref. [45]).
Although diatomite, produced in tons by mining industry, is a cheaper material compared to
diatom frustules, it is still scarcely used in biomedical applications. Recent pioneering papers
demonstrated the use of diatomite silica microshells as microcapsules for oral drug delivery
[17, 20, 47]. For example, indomethacin, an anti-inflammatory drug poorly soluble in water
was explored as model drug in experiments of drug loading and release [18].
More recent works explored the possibility to obtain NPs with a diameter less than 300 nm
from micrometric diatomite powder by means of a process based on mechanical crushing,
sonication, and filtering [30]. The size reduction is fundamental in drug delivery applications
in order to optimize the cellular uptake of particles.
The process for diatomite nanoparticles (DNPs) fabrication is briefly described as follows.
About 5 g of diatomite powder was dissolved in 250 ml of absolute ethanol and sonicated for
5 h in order to break up macroscopic aggregates. The dispersion was then filtered through a
nylon net filter with pore size of 41 μm (Millipore). In order to remove the organic and
inorganic contaminants [34, 36] from natural diatomite, purification treatments were per‐
formed: the diatomite dispersion was then centrifuged and the pellet suspended in piranha
solution (2 M H2SO4, 10% H2O2) for 30 min at 80°C. Dispersion was again centrifuged for 30
min at 13,500 rpm, and the supernatant removed. Next, diatomite was washed twice with
deionized water. 5.0 M HCl solution was then added to diatomite and incubated over night at
80°C. After HCl incubation, the diatomite dispersion was centrifuged for 30 min and the
supernatant removed. The pellet was then washed twice with deionized water in order to
remove the excess of HCl.
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Figure 3. (A) SEM images of diatomite frustules before size reduction treatments and corresponding histogram of par‐
ticles size distribution. (B) SEM images of diatomite particles after size reduction and corresponding histogram of par‐
ticles size.
Figure 3 shows the scanning electron microscope (SEM) images of diatomite fragments before
(A) and after (B) size reduction. Before treatments, diatomite was composed by fragments with
circular, elliptical, elongated, and squared shape. The histogram of particle size showed
dimensions distribution ranging from few microns up to about 40 μm with an average
maximum size of 7 μm. From these images, it was also possible to appreciate the porous
morphology of diatomite useful for drug loading. Morphological characterization, performed
after size reduction and purification, revealed the presence of diatomite fragments with
different shape and size distribution, ranging from few nanometers to about 1 μm, with an
average maximum size of 250 nm. Size of polydispersity can be reduced performing more
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filtration steps using filters of 0.45 μm. After nanometric size reduction, it is still possible to
observe the porous structure of the NPs with pores of about 40 nm in size.
Dynamic light scattering (DLS) analysis was used in order to investigate size and surface
charge of the purified diatomite NPs in water (pH = 7). Figure 4 shows size and zeta-potential
distributions with average values of 220 ± 90 nm and −19 ± 5 mV, respectively. The negative
value of zeta potential is due to Si–OH groups present on the surface of DNPs after piranha
treatment.
Figure 4. Size (A) and zeta-potential (B) distributions of diatomite nanoparticles in water (pH = 7) (Reproduced from
Ref. [30]).
A critical issue for biomedical applications of new drug delivery nanocarriers is the evaluation
of their potential toxicity and biocompatibility [17, 48, 49]. In vitro cytotoxicity of DNPs can be
evaluated by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a
method based on the reduction of MTT by cellular oxidoreductases of viable cells that yield
the formation of crystalline blue formazan. Human lung epidermoid carcinoma (H1355) cells
were used as an in vitro cell model to test the cytotoxicity of DNPs. H1355 cells were incubated
with different concentrations of diatomite NPs for 24, 48, and 72 h. The obtained results are
shown in Figure 5. H1355 cells exposed to increasing NP concentrations (20, 100, 200 and 300
μg/ml) show an average viability lower than 100%, demonstrating a very low toxicity of NPs
and confirming their potentialities as nanovectors in nanomedicine [50, 51].
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Figure 5. Cytotoxicity assessment of DNPs using MTT assay. Cell viability of H1355 cells treated with 20, 100, 200, and
300 μg/ml of nanoparticles for 24, 48, and 72 h at 37°C. Data represent the mean ± s.d. (n = 3). Cell viability was ex‐
pressed as the percentage of viable cells compared with cells cultured without NPs as control (100%) (Reproduced
from Ref. [31]).
3. siRNA delivery by DNPs inside cancer cells
Small interfering ribonucleic acid (siRNA) is a powerful approach for silencing genes associ‐
ated with a variety of pathologic conditions, but its systemic delivery is inefficient due to the
difficulty to penetrate the cell membrane [52, 53]. siRNA conjugation to nanovectors (e.g.,
liposomes, gold and magnetic NPs, quantum dots) is one of the possible strategies developed
to overcome this challenging problem [54, 55]. DNPs have been shown as potential nanocar‐
riers for siRNA transport inside cancer cells and gene expression silencing [31].
siRNA* (labeled with Dy547), complexed with a poly-D-Arg peptide, was loaded onto DNPs
following the functionalization procedure sketched in Figure 6. Briefly, (3-aminopropyl)trie‐
thoxysilane (APTES)-functionalized diatomite reacts with N-(γ -maleimidobutyryloxy)
sulfosuccinimide (NHS) ester (sulfo-GMBS), a water-soluble amine-to-sulfhydryl crosslinker
that contains NHS-ester and maleimide reactive groups at opposite ends of a short spacer arm
that allow covalent conjugation of amine-(diatomite surface) and sulfhydryl-containing
molecules (peptide). A poly-arginine peptide and a nonpolar homopeptide, used as negative
control, were used in a molar nitrogen/phosphate ratio of 20:1, previously described as optimal
condition to form a stable complex with siRNA [31].
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Figure 6. Functionalization scheme of diatomite frustules with labeled siRNA (siRNA*) (Reproduced from Ref. [31]).
In order to study the uptake and intracellular localization of the nanoparticles, H1355 cells (50
× 103/coverslip) were incubated with 300 μg/ml of siRNA* modified DNPs (DNPs-siRNA*) for
24 h. A representative confocal microscopy acquisition was reported in Figure 7.
Figure 7. Confocal microscopy on cells treated with siRNA*-modified diatomite nanovectors (first line) and untreated
cells as control (second line). Cell nuclei and membranes were stained with Hoechst 33342 and WGA-Alexa Fluor 488,
respectively. siRNA was labeled with Dy547. Scale bar corresponds to 20 μm.
Cell nuclei were stained with Hoechst 33342 (blue), whereas WGA-Alexa Fluor 488 (green)
and Dy547 (red) were used to stain cell membranes and siRNA, respectively. In Figure 7, the
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cytoplasmic localization of DNPs-siRNA* is well evident and it was observed as both spots
and diffuse signal [56–59]; no red fluorescence was found inside the nuclei. The efficiency of
DNPs-siRNA* internalization was quantified by fluorescence microscopy: counting the
number of red fluorescent cells and the total number of cells (determined in bright field), a
ratio of about 75% was calculated.
The capability of a siRNA direct toward glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), conjugated on DNPs, to determine gene knockdown, was evaluated by Western
blot analysis; a scramble (SCR) siRNA was used as negative control. A conventional transfec‐
tion method (Lipofectamine 2000) was carried out to compare the two siRNA uptake systems
[31].
The obtained results are showed in Figure 8. The densitometric analysis of the bands (Panel
B) shows a decrease in the GAPDH protein expression (Panel A, upper gel) of about 22% (lane
2) after 48 h incubation at 37°C with respect to control and DNPs-SCR-siRNA-treated cells
(lane 1 and lane 3, respectively). The analysis of GAPDH expression level when lipofectamine
was used is reported in panels C and D; a down-regulation of about 20% is observed.
Figure 8. (A) Immunoblotting analysis of GAPDH (upper gel) and β-tubulin (lower gel) protein expression in DNPs-
siRNA-treated cells. Lanes: (1) control cells; (2) DNPs-GAPDH-siRNA; (3) DNPs-SCR-siRNA. (B) Densitometric inten‐
sity band ratio of GAPDH and β-tubulin used as internal control. The intensities of the bands were expressed in
arbitrary units. (C) Immunoblotting analysis of GAPDH (upper gel) and β-tubulin (lower gel) protein expression in
lipofectamine-siRNA transfected cells. Lanes: (1) control cells; (2) GAPDH-siRNA; (3) SCR-siRNA. (D) Densitometric
intensity band ratio of GAPDH and β-tubulin used as internal control. The intensities of bands were expressed in arbi‐
trary units. Each measurement and Western blot were carried out in triplicate. Error bars indicate the maximum devia‐
tion from the mean value of two independent experiments (Reproduced from Ref. [31]).
Nevertheless, the decrease in the protein expression obtained with the two delivery methods
was comparable; the use of diatomite as nanovectors allows high stability, biocompatibility,
biodegradability, together with high payloads of drugs, selective cell targeting, co-delivery of
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molecules functioning with a different mechanism of action (e.g., drugs and siRNA) and
controlled release of active compounds at the molecular level.
4. Dual-biofunctionalization of DNPs for enhanced stability,
biocompatibility, and cellular internalization in cancer cells
The small size, appropriate aqueous solution stability, biocompatibility, and cellular uptake
are the most important characteristics of NPs as drug delivery systems. The PEGylation [i.e.,
the covalent attachment of poly(ethylene glycol)] of NPs has been frequently used in the design
of drug nanocarriers, as a valid functionalization to improve physico-chemical properties of
NPs such as the increase of their stability in aqueous medium reducing the nonspecific
aggregation and improving biocompatibility, drug loading, and cellular internalization [60–
62]. Moreover, an efficient approach to improve the NPs’ cellular uptake is to bind them to
peptides that can cross the cellular membranes, enhancing their translocation inside the cells
[63]. A valid strategy to improve the intracellular drug delivery of nanocarriers is their
bioconjugation with cell-penetrating peptide (CPP), due to the CPP property to overcome the
Figure 9. (A) Schematic representation of the DNPs functionalization. Reaction I, the PEGylation of DNPs-APT (I) via
EDC/NHS, under stirring overnight (ON) at room temperature. Reaction II, CPP-peptide bioconjugation of DNPs-
APT-PEG via EDC/NHS, under stirring ON at room temperature. (B) ATR-FTIR spectra of DNPs before the biofunc‐
tionalization, after the silanization process, after the PEGylation, and also after the CPP-peptide bioconjugation. The a
indicates CHx stretching vibration, b the bending mode of the free NH2, c the C–N stretching, d the C–H bending vi‐
brations, and c-I and c-II N–H bending vibration, and the C–N stretching vibration, respectively.
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lipophilic barrier of the cellular membranes and deliver NPs inside the cells [64, 65]. PEGyla‐
tion and CPP bioconjugation have been used as biofunctionalization strategies to improve the
physico-chemical and biological properties of the DNPs, in order to enhance the intracellular
uptake in cancer cells and to increase the biocompatibility of APTES modified-DNPs (DNPs-
APT) [66]. The decoration of NPs’ surface with PEG chains was achieved via covalent bond
between the carboxyl groups (–COOH) of PEG molecules and the amino groups (–NH2) of
silanized DNPs using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/NHS chemistry
(Figure 9A, I) [30, 31]. Subsequently, the free amino groups of DNPs-APT-PEG were chemi‐
cally conjugated with the carboxyl groups of CPP, by EDC/NHS chemistry (Figure 9A, II) [67].
The improvement of the NPs’ stability in aqueous solutions was confirmed by hydrodynamic
diameter, PDI, and surface charge ζ-potential measurements, before and after the DNPs’
surface modification. A progressive decrease of the nano-aggregates size from 364 ± 3 nm
(DNPs-APT) to 346 ± 4 nm after PEGylation (DNPs-APT-PEG), and to 340 ± 8 nm after CPP-
conjugation (DNPs-APT-PEG-CPP), was observed. This result is due to an increase of the DNPs
surface repulsion forces of the modified surface (DNPs-bare,−19.2 ± 2.0 mV; DNPs-APT, +19.8
± 3.0 mV; DNPs-APT-PEG, +35.6 ± 1.5 mV; DNPs-APT-PEG-CPP, +40 ± 2 mV), which can be
attributed to the positive charge of PEG-peptide and CPP onto the NPs’ surface. The result of
DNPs modification was also evaluated by attenuated total reflectance Fourier transform
infrared spectroscopy (ATR–FTIR). Figure 9B shows the progressive change of DNPs FTIR
spectra after each modification step. After the silanization process, the DNPs-APT displayed
the typical bands of APTES corresponded to the CHx stretching at 2941–2570 cm−1, the free
NH2 bending mode at 1630–1470 cm−1, and the C–N stretching at 1385 cm−1 [68, 69]. After the
PEGylation, the DNPs-APT-PEG showed the stretching bands of the CHx at 2960–2849 cm−1,
the C–H bending vibrations at 2160–1722 cm−1, the amide I band at 1640 cm−1 associated with
the C=O stretching vibration, the amide II resulted from the N–H bending vibration, and the
C–N stretching vibration at 1580 and 1360 cm−1, respectively, thus confirming the covalent
binding of the PEG molecules onto the NPs’ surface [69]. After incubation with the CPP-
peptide, the DNPs-APT-PEG-CPP displayed a band of the CHx stretching at 2984–2881 cm−1,
and the C–N stretching of amide II at 1930 cm−1, confirming the successful of CPP-peptide
bioconjugation onto DNPs surface [69, 70].
The hemocompatibility of NPs is of critical importance for their systemic administration as
drug delivery systems, in order to avoid serious risks to human health [71, 72]. The effect of
modified-DNPs on red blood cells (RBCs) was evaluated studing the % lysed RBCs and their
morphology after exposure to the NPs at increasing incubation times (1, 4, 24, 34 and 48 h) and
concentrations (25, 50, 100, and 200 μg/ml) [66, 73]. The NPs hemotoxicity was qualitatively
determined by naked-eye color evaluation of RBCs’ supernatant incubated with modified-
DNPs, observing an higher hemotoxicity degree of the DNPs-APT than PEG and CPP
modified-DNPs, since the red color intensity of DNPs-APT-RBCs supernatant was closer to
the positive control one (water), as shown in Figure 10A. The %-hemolysis determined by
spectrophotometric analysis of the supernatants after 48 h incubation at the maximum
concentration of modified-DNPs (200 μg/mL) was 34% for DNP-APT, 7% for DNP-PEG, and
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1.3% for CPP-DNP, demonstrating that the dual-biofunctionalization improved the DNPs
hemocompatibility (Figure 10B).
Figure 10. (A) Representative pictures of the RBCs after interaction with the modified-DNPs. The DNPs were incubat‐
ed with the cells for 48 h and at different concentrations (25, 50, 100, and 200 μg/ml). (B) Hemotoxicity of APT-, PEG-,
and CPP-modified DNPs incubated for 48 h at different concentrations (25, 50, 100, and 200 μg/ml) with RBCs, estimat‐
ed by spectrophotometric methods (577 nm) to analyze the amount of lysed-hemoglobin in the supernatants. The level
of significance from negative control was set as probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001 by ANOVA. Error
bars represent s.d. (n = 3).
Figure 11. SEM pictures of the RBCs morphological modification after the exposure to the modified DNPs. The modi‐
fied DNPs (100 μg/ml) were incubated with RBCs for 4 h at room temperature. The DNPs-APT showed the higher tox‐
icity than the PEG and CPP-modified DNPs, resulting in severe morphological changes of cell. The CPP-
bioconjugation improved significantly the DNPs–cells membrane interactions, as indicated by white arrows. Scale bars
are 3 μm (Reproduced from Ref. [66] with permission from the Royal Society of Chemistry).
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Figure 11 shows SEM characterization of RBCs after exposure to the modified-DNPs (200 μg/
ml for 4 h at room temperature). The RBCs, in the presence of DNP-APT completely altered
their morphology, changing from the biconcave-like disks to shrinked shape, with consequent
hemolysis due to the free positive amine groups on the surface of the NPs, which strongly
interact with the negative charge surface of the RBCs. In the case of PEGylated particles, there
was a slight change in the RBC’s morphology by membrane wrapping around with the
appearance of small holes, but without significant hemolysis. The relevant decrease of the
DNPs-APT hemotoxicity after PEGylation is due to the improved biocompatibility of the NPs
as a result of PEGylation [74, 75]. In the case of DNPs-APT-PEG-CPP, there were no relevant
changes observed in the morphology due to the low cytotoxicity of CPP-peptide, which
improved the DNPs’ biocompatibility [76–78].
Efficient delivery of the nanocarriers to the cells and tissues is another key requirement for
drug delivery applications. The CPP-peptide, used to improve the cellular uptake of the DNPs,
is a short cationic peptide with intrinsic ability to enter cells and mediate uptake of a wide
range of molecular cargos, such as oligonucleotides, small molecules, siRNA, NPs, peptides,
and proteins [79–81].
Figure 12. (A) TEM images of MDA-MB-231 cells treated with 50 μg/ml of DNPs-APT, DNPs-APT-PEG, and DNPs-
APT-PEG-CPP for 12 h at 37°C. A very small amount of APTES- and PEG-modified DNPs (in dotted boxes) was found
inside the cells. In the case of DNPs-APT-PEG-CPP (in dotted boxes), a considerable amount of the NPs was observed
inside the cells. Scale bars are 10 μm. (B) Confocal fluorescence microscopy MDA-MB-231 cells treated with 50 μg/ml
of APT, APT-PEG, APT-PEG-CPP modified-DNPs for 12 h at 37°C. CellMask® (red) and Alexa Fluor-488® (green) were
used to label the cells membrane and the DNPs, respectively. The merge figures are obtained by overlapping the DNPs
and the cells membrane images, allowing to determine whether the NPs are located outside (green color) or inside
(yellow color) the cells.
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The cellular uptake of modified DNPs was evaluated by transmission electron microscope
(TEM), after the incubation of MDA-MB 231 breast cancer cells with the NPs (50 μg/mL) for
12 h. In Figure 12A, the APTES-modified DNPs were mainly localized in the proximity of the
cell membrane, while in the case of the DNPs-APT-PEG, any significant cellular uptake was
observed. For the CPP-modified NPs, a considerable amount of DNPs was internalized into
the cells with a homogeneous distribution into the cytoplasm and very close to the nucleus.
The cellular uptake was also evaluated by confocal fluorescence microscope after DNPs and
cellular membrane labeling with Alexa Fluor-488® and CellMask™ Deep Red, respectively
(Figure 12B). In merged images, for DNPs-APT, the green color is indicative of the presence
of DNPs on the cell membrane surface; while for the CPP modified-DNPs, the yellow color,
resulting from the co-localization of the green labeled-DNPs and red-stained cancer cell
membranes, is representative of NPs located inside the cells. These results confirmed that the
CPP bioconjugation is a valid functionalization strategy to increase the cell penetration of
DNPs [82, 83].
5. In vivo evaluation of DNPs toxicity
In vitro testing is the most common scientific analysis used to determine the effects of NPs
toxicity. However, the success of in vitro assays is not predictive for promising in vivo results;
for this reason, in vivo evaluation of NPs toxicity is a crucial issue in order to develop safe
nanodevices for biomedical applications.
In this context, Hydra vulgaris (Cnidaria, Hydrozoa) was used as preliminary in vivo model to
evaluate diatomite NPs toxicity.
Hydra is a simple multicellular organism at the base of the metazoan evolution. It consists of
a tube which is made of two connected epithelial cell layers: the outer ectoderm and inner
endoderm, separated by an acellular mesoglea layer (Figure 13) [84]. As shown in Figure 13,
at the top end of the tube, there is the hypostome composed by a mouth surrounded by 6–8
tentacles that contain the most part of stinging cells (cnidocytes or nematocytes) that let Hydra
to catch its prey [85]. Hydra column has four distinctive sections: the gastric region located
between the tentacles and the first (apical) bud; the budding section, which produces the buds;
the peduncle, which is located between the lowest bud and basal disc; and the basal disc, which
is the foot-like formation [86]. This structural complexity, simpler than vertebrates with central
nervous system and specialized organs, but more complex than cultured cells, makes Hydra
comparable to a living tissue whose cells and distant regions are physiologically connected. It
possesses a simple nervous system consisting of a diffuse nerve net throughout the body [87].
Hydra typically reproduces asexually resulting in the rapid production of a large number of
new organisms that can be cultured in a short period of time. Hydra is sensitive to a range of
pollutants and has been used as a biological indicator of water pollution [88]. Metal pollutants
such as copper, cadmium, and zinc have been tested against different Hydra species, and the
relative toxicity based on the median lethal concentration (LC50) for all species was ranked
from copper, the most toxic, to cadmium with zinc, the least toxic [88].
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Figure 13. Anatomical structure of Hydra vulgaris. The inset shows the bilayer structure characterizing the whole body,
from the foot to the tentacles, that is, the ectoderm and endoderm layers separated by the mesoglea. The few special‐
ized cell types differentiated by the interstitial stem cells are shown (neurons, cnidocyte, gland cells).
Hydra has also been used as alternative in vivo model, to study the toxicity of different NPs, as
well as their uptake and fate [89–91]. Due to a simple tubular body and being diploblastic, an
even exposure of the whole animal to NPs by simple soaking is allowed [92, 93]. Several
bioassays are available to assess the toxicity of a given substance in terms of acute or sub-lethal
toxicity [94]. Hydra exposure to different substances may cause alteration of (1) morphological
traits and developmental programs, (2) regeneration or pattern formation, and (3) population
growth rates.
Toxicity of a substance is conventionally measured in Hydra observing changes in the animal
morphology following Wilby’s classification ranging from score 10 (normal, elongated
tentacles and body), 8 (clubbed or bulged tentacles), 6 (shortened tentacles), 5 (tulip phase), 2
(loss of osmoregulation), to 0 (disintegrated) [95]. Scores 10–6 are reversible, sub-lethal
indicators, while the tulip phase (score 5 and below) is considered irreversible and used as the
endpoint for lethality [92, 95].
Toxicity of diatomite NPs in Hydra was investigated monitoring changes in its morphology
after exposure to DNPs at increasing incubation times (24, 48 and 72 h) and concentrations
(0.5, 1, 1.5, 2.5, 3, 3.5, and 4 mg/mL). Hydra vulgaris was asexually cultured in physiological
solution by the method of Loomis and Lenhoff with minor modifications [96]. The animals
were kept at 18°C and fed three times per week with freshly hatched Artemia salina nauplii.
All animals were starved 24 h prior to the experiments. For each DNPs concentration, twenty
polyps were used [97]. Either control or treated animals were placed into plastic multiwells
refreshing the medium every 24 h. The morphophysiological effects of DNPs on Hydra were
recorded by microscopic examination of each polyp and used to extrapolate the Wilby’s score
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key. A representative in vivo image of Hydra after exposure to DNPs is reported in Figure 14.
Any change in polyp morphology was not observed after exposure to DNP concentrations up
4 mg/mL for 72 h; this result corresponds to score 10 of Wilby’s classification.
Figure 14. In vivo imaging of Hydra polyps treated with DNPs. Polyp morphology is not affected by the nanoparticle
treatment. Scale bar: 1 mm.
These data confirm in vitro toxicity results. The transparency of Hydra epithelium makes it
possible to track and localize fluorescent nanoparticles in the animal body [92–94]. The
internalization of DNPs in Hydra was evaluated by in vivo fluorescence microscopy analysis,
after labeling DNPs by Alexa Fluor-488® (DNPs*). Ten living Hydra were treated with DNPs*
(3.5 mg/mL) up to 72 h. Bright-field and fluorescence images of Hydra polyps treated with
DNPs* for 24 (C, D) and 72 h (E, F) are reported in Figure 15; Figure 15A, B shows an untreated
animal as control. In all figures, the foot is on the lower part of the panel, while a crown of
tentacles surrounds the mouth. The image taken after 24 h (D) shows an intense fluorescence
of DNPs, distributed in the whole body and confined to the outer ectoderm. After 72 h (F) of
incubation, the DNPs were mainly localized in the inner endodermal cells, due to inter-
epithelial migration of free or cell-containing nanoparticles between the two cell layers [92].
These preliminary in vivo results are in agreement with the in vitro data, confirming that DNPs
could be used as safe and biocompatible nanocarrier for long incubation times and up to high
concentrations.
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Figure 15. In vivo fluorescence imaging of Hydra polyps treated with labeled DNPs (3.5 mg/mL) for different incuba‐
tion times. Scale bars: 1 mm. The fluorescence pattern appears as rather uniform after 24 h of incubation, while at 72 h
it appears as granulates covering most of body regions. They might represent storage vacuoles, as it has been shown
for other fluorescent nanoparticles [92, 94].
6. Conclusions and future trends
Diatomite is a fossil material of sedimentary origin formed over centuries by siliceous skeleton
of aquatic unicellular microalgae diatoms, with similar physico-chemical properties of man-
made fabricated PSi. Due to its ordered pore structure, high surface area, tailorable surface
chemistry, high permeability, biocompatibility, non-toxicity, low cost, optical, and photonic
properties, diatomite has been exploited as an innovative platform in several biotechnological
applications, resulting as a viable and promising cheap alternative to synthetic porous silica.
In this chapter, the potentialities of DNPs, with an average size of about 350 nm, as drug
nanocarriers were discussed. Preliminary tests of cytotoxicity and cellular uptake demon‐
strated the biocompatibility of the DNPs and their capability to penetrate inside cancer cells.
Different functionalization procedures of diatomite surface for preparation of bioengineered
nanovectors were also described. These results, compared with those reported in literature on
standard systems, encourage the use of diatomite-based materials as new class of nanostruc‐
tured drug carriers.
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